Aduro begins trial of MK-5890 for non-small cell lung cancer treatment
Category: #health  By Mateen Dalal  Date: 2020-02-07
  • share
  • Twitter
  • Facebook
  • LinkedIn

Aduro begins trial of MK-5890 for non-small cell lung cancer treatment

The biopharmaceutical giant has also received a USD 10 million development milestone payment from Merck & CO. for the initiation of the trial

A clinical-stage biopharmaceutical company, Aduro Biotech, Inc. recently announced to have bagged a USD 10 million development milestone payment under its worldwide licensing agreement with the leading biopharmaceutical company, Merck & CO., for the initiation of a Phase 2 clinical trial of an anti-CD27 agonist, MK-5890, in NSCLC (non-small cell lung cancer).

For the record, Aduro Biotech is focused on developing therapies targeting the STING (Stimulator of Interferon Genes) and APRIL (A Proliferation Inducing Ligand) pathways for the treatment of autoimmune, inflammatory diseases and cancer.

In preclinical studies, Adoro’s anti-CD27 antibody activation has demonstrated enhanced T-cell response, which in combination with immune checkpoint inhibition has shown the ability to achieve complete tumor eradication. 

Andrea van Elsas, Chief Scientific Officer at Aduro was reportedly quoted saying that the company is elated to witness Merck & CO putting efforts to advance MK-5890 through development with the initiation of a Phase 2 clinical trial in non-small cell lung cancer.

Elsas added saying that the achievement of the recent milestone would not have been possible without the progressive efforts of the exceptional team at Aduro Biotech Europe and the B-select technology,  which have produced various monoclonal antibodies, along with an anti-APRIL antibody, BION-1301 and MK-5890 that the company is currently developing for Berger's disease (IgA nephropathy).

As per sources close to the matter, the Phase 2 clinical trial is designed to assess the safety  and efficacy of pembrolizumab in combination with an anti-CD27 agonist, MK-5890 in patients suffering from advanced non-squamous or squamous NSCLC, that have been treated earlier with anti-PD-L1 therapy. The study is 1 of the 3 pembrolizumab sub-studies that were supposed to be conducted under one pembrolizumab umbrella master protocol.

Source Credit: https://investors.aduro.com/news-releases/news-release-details/aduro-biotech-announces-milestone-achieved-under-merck?field_nir_news_date_value%5bmin%5d=

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Gennova begins enrollment for Phase 1/2 trials of mRNA COVID vaccine
Gennova begins enrollment for Phase 1/2 trials of mRNA COVID vaccine
By Mateen Dalal

India's first mRNA-based COVID-19 vaccine, HGCO19, formulated by Pune-based biotech firm, Gennova Biopharmaceuticals is about to enter its Phase 1/2 clinical trials with the enrollment of candidates, said the Department of Biotechnology (DBT). R...

Mashcor launches new independent search engine for the Afrotech sector
Mashcor launches new independent search engine for the Afrotech sector
By Mateen Dalal

Mashcor, a leading South African digital agency, has reportedly announced the launch of Africa’s first indigenous search engine. The new search engine has been specifically designed to connect the region’s rapidly expanding tech sector to...

Canada and Germany ink new energy partnership with emphasis on hydrogen
Canada and Germany ink new energy partnership with emphasis on hydrogen
By Mateen Dalal

The government of Canada has inked a new, comprehensive energy partnership deal with the government of Germany to set up a formal collaboration across a wide array of shared energy priorities, including hydrogen and LNG. According to reports, this c...